Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

23.44 

-0.30 -1.3%

as of Mar 03 '21

52 Week Range:

13.63 26.75


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 0.96
2.02
0.41
-0.43
0.36
0.29
-0.44
0.53
10.32
8.43
growth rate 110.4% -79.7% -100.0% 100.0% -19.4% -100.0% 100.0% 1,847.2% -18.3%
Earnings BIT -37.06
-132.96
-171.45
-159.77
-16.49
-29.37
-112.86
-43.66
687.93
-440.04
-425.11
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Avg.PE -33.30
-6.40
-5.20
-3.43
-3.43
274.04
274.04
-16.80
9.75
9.75
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 0.0% -100.0% 100.0% 0.0%
ROA -6.92
-23.76
-31.12
-34.75
-12.31
-17.20
-28.67
-17.94
51.25
-21.35
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROE -39.31
-92.89
-140.39
-379.68
-324.73
-109.91
75.47
-28.22
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROIC -9.62
-26.69
-76.54
-27.73
-43.87
-22.44
59.76
-21.84
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Cur. Ratio 5.52
1.00
4.01
2.63
4.50
5.72
5.90
5.82
17.53
4.02
growth rate -81.9% 301.0% -34.4% 71.1% 27.1% 3.2% -1.4% 201.2% -77.1%
Quick Ratio 5.32
0.89
3.60
2.44
3.77
5.37
5.60
5.36
16.81
3.85
growth rate -83.3% 304.5% -32.2% 54.5% 42.4% 4.3% -4.3% 213.6% -77.1%
Leverage 5.75
3.07
10.59
12.16
78.09
6.46
5.79
1.25
1.41
growth rate -46.6% 245.0% 7.2% 542.2% -91.7% -10.4% -78.4% 12.8%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 25.10
4.94
5.81
2.23
3.61
19.95
15.68
5.01
43.21
36.80
38.89
growth rate -80.3% 17.6% -61.6% 61.8% 453.0% -21.4% -68.0% 761.9% -14.8% 5.7%
Acct.Payable 36.25
44.23
53.43
2.70
2.36
2.82
4.78
5.85
19.23
22.14
growth rate 22.0% 20.8% -94.9% -12.6% 19.2% 69.8% 22.4% 228.6% 15.1%
Cur.Assets 354.00
276.71
314.63
257.88
288.20
350.05
425.95
326.82
1,437.69
1,421.55
1,138.01
growth rate -21.8% 13.7% -18.0% 11.8% 21.5% 21.7% -23.3% 339.9% -1.1% -20.0%
Total Assets 521.20
606.55
497.79
434.53
441.62
498.64
568.87
508.87
2,150.17
1,977.36
1,538.77
growth rate 16.4% -17.9% -12.7% 1.6% 12.9% 14.1% -10.6% 322.5% -8.0% -22.2%
Cash 17.80
15.31
25.44
39.07
12.37
55.57
59.64
4.76
194.91
96.36
198.96
growth rate -14.0% 66.1% 53.6% -68.4% 349.4% 7.3% -92.0% 3,992.9% -50.6% 106.5%
Inventory 7.30
12.66
18.27
13.45
12.95
11.35
11.11
10.73
11.38
12.67
15.29
growth rate 73.4% 44.4% -26.4% -3.7% -12.4% -2.1% -3.5% 6.1% 11.3% 20.7%
Cur.Liabilities 64.10
275.53
78.54
98.22
64.05
61.25
72.22
56.16
82.00
353.89
115.78
growth rate 329.9% -71.5% 25.1% -34.8% -4.4% 17.9% -22.2% 46.0% 331.6% -67.3%
Liabilities 430.60
408.74
450.77
524.43
405.29
492.21
480.75
421.04
432.60
571.97
461.47
growth rate -5.1% 10.3% 16.3% -22.7% 21.5% -2.3% -12.4% 2.8% 32.2% -19.3%
LT Debt 232.00
14.58
136.61
133.05
125.00
241.70
243.46
245.21
246.95
growth rate -93.7% 836.8% -2.6% -6.1% 93.4% 0.7% 0.7% 0.7%
Equity 90.70
197.81
47.02
36.33
6.43
88.13
87.83
1,717.58
1,405.39
1,077.30
growth rate 118.1% -76.2% -12.1% -82.3% 1,270.7% -0.3% 1,855.6% -18.2% -23.4%
Common Shares 94.00
113.00
115.00
116.00
127.00
132.00
140.00
156.00
173.53
176.51
180.09
growth rate 20.2% 1.8% 0.9% 9.5% 3.9% 6.1% 11.4% 11.2% 1.7% 2.0%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 31.50
9.72
10.58
4.09
9.98
11.20
6.39
9.68
14.24
26.29
7.26
growth rate -69.1% 8.9% -61.3% 143.9% 12.2% -42.9% 51.4% 47.2% 84.6% -72.4%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA -55.87
-113.74
-129.76
-142.01
-73.08
-117.02
-80.41
718.21
-328.68
-313.29
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
FCF per Share -0.93
-0.64
-1.22
-1.26
-0.58
-0.27
-1.07
-0.41
4.29
-2.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Sale Purchase of Stock 224.31
4.12
8.21
163.52
32.21
209.56
59.52
growth rate -98.2% 99.4% 1,892.2% -80.3% 550.7% -71.6%
FCF -87.00
-123.00
-140.00
-43.00
-152.00
-84.00
-123.00
-90.00
704.00
-355.00
-320.55
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 159.00
71.48
81.19
148.92
200.71
230.78
165.44
307.71
1,171.74
93.31
146.06
growth rate -55.0% 13.6% 83.4% 34.8% 15.0% -28.3% 86.0% 280.8% -92.0% 56.5%
Op.Income -28.30
-133.98
-171.86
-162.01
-16.49
-29.37
-112.86
-43.66
687.93
-440.04
-425.11
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
IBT -37.10
-132.96
-171.45
-159.77
-54.43
-80.67
-152.65
-96.08
682.73
-440.05
-443.95
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Net Income -37.90
-133.98
-171.86
-162.01
-53.92
-81.18
-153.52
-96.69
681.31
-440.67
-444.44
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
EPS -0.40
-1.19
-1.50
-1.40
-0.42
-0.61
-1.10
-0.62
3.78
-2.52
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Gross Profit 133.40
49.59
50.76
110.41
172.17
196.68
135.22
277.16
1,147.33
71.93
126.59
growth rate -62.8% 2.4% 117.5% 55.9% 14.2% -31.3% 105.0% 314.0% -93.7% 76.0%
R&D 108.10
126.77
148.68
190.01
144.53
179.59
203.80
268.46
-399.54
-434.57
-408.68
growth rate 17.3% 17.3% 27.8% -23.9% 24.3% 13.5% 31.7% -100.0% 0.0% 0.0%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT -109.64
-133.63
-77.71
-103.05
-110.72
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 36.80
48.23
78.35
48.33
38.89
growth rate 31.1% 62.4% -38.3% -19.5%
Acct.Payable 19.23
21.79
19.25
15.48
22.14
growth rate 13.3% -11.7% -19.6% 43.0%
Cur.Assets 1,421.55
1,429.32
1,151.97
1,043.86
1,138.01
growth rate 0.6% -19.4% -9.4% 9.0%
Total Assets 1,977.36
1,887.93
1,594.88
1,508.67
1,538.77
growth rate -4.5% -15.5% -5.4% 2.0%
Cash 96.36
227.04
58.21
55.84
198.96
growth rate 135.6% -74.4% -4.1% 256.3%
Inventory 12.67
14.32
12.58
12.89
15.29
growth rate 13.1% -12.1% 2.5% 18.6%
Cur.Liabilities 353.89
377.47
123.96
126.50
115.78
growth rate 6.7% -67.2% 2.1% -8.5%
Liabilities 571.97
591.51
338.64
337.69
461.47
growth rate 3.4% -42.8% -0.3% 36.7%
LT Debt
growth rate
Equity 1,405.39
1,296.43
1,256.24
1,170.98
1,077.30
growth rate -7.8% -3.1% -6.8% -8.0%
Common Shares 176.51
177.86
178.81
179.39
180.09
growth rate 0.8% 0.5% 0.3% 0.4%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 3.67
0.90
2.69
1.91
1.75
growth rate -75.5% 199.3% -29.1% -8.2%
Cash Dividends
growth rate
Cash From OA -83.83
-78.08
-83.90
-52.68
-127.59
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -87.50
-78.98
-86.60
-54.59
-129.35
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 33.86
50.57
48.85
30.03
23.46
growth rate 49.4% -3.4% -38.5% -21.9%
Op.Income -109.64
-133.63
-77.71
-103.05
-110.72
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -111.89
-138.45
-79.86
-108.57
-117.08
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -112.16
-138.65
-80.00
-108.59
-127.59
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 27.87
46.76
43.07
24.46
19.14
growth rate 67.8% -7.9% -43.2% -21.8%
R&D -110.37
-108.99
-96.44
-100.53
-102.72
growth rate 0.0% 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 9.75 4.36 -36.65
EPS / Growth 0.0% 5.38 -7.3%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 17.0% 19.2%
Future PE 0.00 6.50 16.05
Future EPS 5.38 25.84 31.13
Value Price
MOS %
0.00
-100.0%
41.54
77.2%
123.54
427.0%
MOS Price 0.00 20.77 61.77
IRT 4.36 3.12 3.03

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.